- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Terrill Jordan Discusses OCM Performance Period 4 Results
Terrill Jordan, chief executive officer of Regional Cancer Care Associates, discusses Oncology Care Model performance period 4 results and the biggest challenges community oncologists continue to face when trying to perform under the model.
Terrill Jordan, chief executive officer of Regional Cancer Care Associates, discusses Oncology Care Model performance period 4 results and the biggest challenges community oncologists continue to face when trying to perform under the model.
Transcript
With OCM Performance Period 4 results now out, how did the results compare with performance periods 2 and 3?
When you look at performance period 4 relative to performance periods 2 and 3, I think overall what you find is there is still some questions that are coming out. Each performance period we find there are some unresolved issues and then there are some new issues that we’ve encountered. So, I think there’s still some challenges. We’re excited to continue that journey. I think as we get more and more data points over time, we’ll have a better sense of what actually happened over the transition from performance period 1 all the way to performance period 9.
What continue to be the biggest pain points practices experience when trying to perform well under OCM?
I think the pain points that we’ve experienced are exactly the same as they always have been. You have to be efficient in this business be competitive as an independent practice, and we don’t have the resources, we’re not resource rich like a hospital. So, you have to use your resources appropriately, you have to make sure you maximize your resources. So, I think that challenge hasn’t changed and I think we’ll see that pain point continue.
I go back to being here at OncoCloud—the technology is the key differentiator. Our ability to use technology to further our practices, to further the clinicians license is really what’s going to distinguish us from a hospital. We should be able to do this better—we’re smaller, more nimble, and more importantly, we have the flexibility. You don’t have the bureaucracy that a hospital would face, and most importantly, we’re clinician led, so our clinicians are the ones who really decide what happens in our practices.
New Insights Into Meth-Associated PAH Care Gaps: Anjali Vaidya, MD, on Closing the Divide
June 4th 2025Research from Anjali Vaidya, MD, FACC, FASE, FACP, Temple University Hospital, reveals critical care gaps for patients with methamphetamine-associated pulmonary arterial hypertension (PAH), emphasizing the need for early diagnosis and integrated support.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD
May 17th 2025Novel therapies for multiple myeloma (MM), including chimeric antigen receptor T-cell and bispecific antibodies, extend lives but raise concerns about treatment costs and adherence, and they haven't replaced stem cell transplantation, Harsh Parmar, MD, of Hackensack University Medical Center, explains.
Read More
Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD
April 25th 2025When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.
Read More
